ArticleDiscover oncology2025
A Mendelian randomization study investigating the causal associations of 35 blood and urinary metabolite biomarkers with breast cancer development.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Breast cancer is the most common cancer among women worldwide. The present study utilized a bidirectional Mendelian randomization methodology to explore the causal associations between 35 blood and urinary metabolic markers and distinct subtypes of breast cancer. The MR-PRESSO method was employed to detect and correct for pleiotropic effects, with statistical significance adjusted using the false discovery rate (FDR). The findings revealed significant causal links between certain metabolic markers and specific breast cancer subtypes. Specifically, glucose (OR: -0.187; 95% CI: -0.344 to -0.030) and glycated hemoglobin (HbA1c) (OR: -0.150; 95% CI: -0.2498 to -0.051) were associated with benign breast cancer. In contrast, statin-adjusted apolipoprotein B (OR: 0.493; 95% CI: 0.029 to 0.957) and low-density lipoprotein (LDL) (OR: 0.550; 95% CI: 0.056 to 1.043), urinary sodium (OR: -3.138; 95% CI: -5.710 to -0.565), and triglycerides (OR: 0.606; 95% CI: 0.0824 to 1.129) were correlated with intraductal carcinoma in situ. Apolipoprotein A (OR: 0.178; 95% CI: 0.053 to 0.304) and high-density lipoprotein (HDL) cholesterol (OR: 0.159; 95% CI: 0.045 to 0.273) were linked to intraductal carcinoma in situ of the breast, while total protein (OR: 0.800; 95% CI: 0.181 to 1.409) and albumin (OR: 0.883; 95% CI: 0.255 to 1.512) were associated with lobular carcinoma in situ. In the reverse analysis, benign breast cancer (OR: 0.014; 95% CI: 0.002 to 0.026) exhibited a correlation with urinary creatinine, and intraductal carcinoma in situ (OR: 0.004; 95% CI: 0.001 to 0.007) with insulin-like growth factor 1 (IGF-1). This study identifies key biomarkers for breast cancer susceptibility and resistance, offering a scientific foundation for further research endeavors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.